Across TCGA pan-cancer cohorts, BLM Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated BLM data layer compared with 30 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher BLM Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated BLM expression acts as an unfavorable survival marker, although some lineages such as UCEC and SKCM show a favorable association.

UCEC, SCLC, and STAD are the cancer types where BLM Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	DFS	Median	All	0.972	0.614	.003	36	view →
SCLC	OS	Median	All	0.082	0.653	.002	6	view →
STAD	OS	Median	IV	0.001	0.544	<.001	6	view →
SKCM	OS	Median	II,III,IV	1.000	0.723	.017	5	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: BLM tumor-vs-normal RNA expression · all BLM data types